Acorda Therapeutics Appoints Michael Rogers Chief Financial Officer; David Lawrence Named Chief of Business Operations

  Acorda Therapeutics Appoints Michael Rogers Chief Financial Officer; David
  Lawrence Named Chief of Business Operations

Business Wire

ARDSLEY, N.Y. -- October 7, 2013

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers
has joined the Company as Chief Financial Officer (CFO), effective October 7,
2013. He will assume responsibility for the Company’s Finance and Investor
Relations departments. David Lawrence, M.B.A., who previously served as CFO,
has been appointed Chief of Business Operations (CBO) and will be responsible
for Technical Operations/Manufacturing, Project Management, Information
Technology and Facilities Management.

“I’m delighted to welcome Mike Rogers to Acorda’s senior management team. Mike
has a record of success as CFO at both commercial- and development-stage
biotechnology companies, as well as a background in investment banking,” said
Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “Mike’s
strategic insight and broad experience will help us capitalize on
opportunities to expand Acorda’s business and continue to deliver shareholder

Mr. Rogers joins Acorda with 22 years of experience in the biopharmaceutical
industry. Most recently, he served as Executive Vice President and CFO of BG
Medicine, Inc., where he led the company’s successful initial public offering
(IPO) in 2011 and was instrumental in assisting in the launch of that
company’s first product in the cardiovascular area. Prior to that, Mr. Rogers
served as the CFO of Indevus Pharmaceuticals for 10 years until the company’s
sale to Endo Pharmaceuticals. He has led multiple private and public
financings and had a central role in numerous mergers and acquisitions over
the course of his career, which includes both in-house leadership positions
and serving as an external financial advisor.

Mr. Rogers said, “Acorda has emerged as a leading biopharmaceutical company in
the neurology space. I look forward to working with Ron, the Board and the
management team to help guide the Company to its next levels of growth. It’s
an exciting time to join Acorda. In addition to its commercial success, the
Company has a deep pipeline of potential near-term commercial products and
clinical development-stage programs.”

Commenting on Mr. Lawrence’s new role as Chief of Business Operations at
Acorda, Dr. Cohen said, “Acorda is now at a stage that requires focused
leadership of our business operations. Dave has been a key contributor to
building the Company over the last 15 years, and we are fortunate to continue
to benefit from his capabilities as he expands his role within Acorda.”

Mr. Lawrence said, “We’ve grown rapidly over the past several years, and our
internal operations need to keep pace with the demands of the business. I’m
excited to take on this new challenge at Acorda, overseeing and optimizing
development of our business operations and infrastructure. These are
increasingly critical to supporting the Company’s work to develop therapies
that make a difference in the lives of people with neurological diseases.”

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on
developing therapies that restore function and improve the lives of people
with neurological conditions.

Acorda markets three FDA-approved therapies including: AMPYRA^®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES^®
(tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the
management of spasticity; and QUTENZA^® (capsaicin) 8% Patch, for the
management of neuropathic pain associated with postherpetic neuralgia. AMPYRA
is marketed outside the United States as FAMPYRA^® (prolonged-release
fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological
therapies. The Company is currently developing six clinical-stage therapies
and one preclinical stage therapy that address a range of disorders including
post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve
damage, spinal cord injury, neuropathic pain, and heart failure. For more
information, please visit the Company’s website at:

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including our ability to successfully market and
sell Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development programs,
including Diazepam Nasal Spray or any other acquired or in-licensed programs;
we may not be able to complete development of, obtain regulatory approval for,
or successfully market Diazepam Nasal Spray or other products under
development; the occurrence of adverse safety events with our products; delays
in obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our collaboration
partnerBiogen Idecin connection therewith; competition, including the impact
of generic competition on Zanaflex Capsules revenues; failure to protect our
intellectual property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and the
ability to obtain additional financing to support our operations. These and
other risks are described in greater detail inAcorda Therapeutics'filings
with the Securities & Exchange Commission.Acordamay not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this


Acorda Therapeutics
Jeff Macdonald, 914-326-5232
Press spacebar to pause and continue. Press esc to stop.